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ABSTRACT Human noroviruses (HuNoVs) cause significant morbidity and mortality worldwide. However, despite substantial
efforts, a small-animal model for HuNoV has not been described to date. Since “humanized” mice have been successfully used to
study human-tropic pathogens in the past, we challenged BALB/c mice deficient in recombination activation gene (Rag) 1 or 2
and common gamma chain (c) (Rag-c) engrafted with human CD34 hematopoietic stem cells, nonengrafted siblings, and
immunocompetent wild-type controls with pooled stool isolates from patients positive for HuNoV. Surprisingly, both human-
ized and nonhumanized BALB/c Rag-c-deficient mice supported replication of a GII.4 strain of HuNoV, as indicated by in-
creased viral loads over input. In contrast, immunocompetent wild-type BALB/c mice were not infected. An intraperitoneal
route of infection and the BALB/c genetic background were important for facilitating a subclinical HuNoV infection of Rag-c-
deficient mice. Expression of structural and nonstructural proteins was detected in cells with macrophage-like morphology in
the spleens and livers of BALB/c Rag-c-deficient mice, confirming the ability of HuNoV to replicate in a mouse model. In sum-
mary, HuNoV replication in BALB/c Rag-c-deficient mice is dependent on the immune-deficient status of the host but not on
the presence of human immune cells and provides the first genetically manipulable small-animal model for studying HuNoV in-
fection.
IMPORTANCE Human noroviruses are a significant cause of viral gastroenteritis worldwide, resulting in significant morbidity and
mortality. Antivirals and vaccines are currently not available, in part due to the inability to study these viruses in a genetically
manipulable, small-animal model. Herein, we report the first mouse model for human noroviruses. This model will accelerate
our understanding of human norovirus biology and provide a useful resource for evaluating antiviral therapies.
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Human noroviruses (HuNoVs) are the leading etiologic agentof viral epidemic gastroenteritis globally in people of all ages
(1), causing an estimated 200,000 deaths each year in children
under 5 years old in developing countries (2). In the United States,
~21 million cases of gastroenteritis and ~800 deaths due to
HuNoV occur annually, making HuNoV infections the leading
cause of death among individuals with viral gastroenteritis (3, 4).
Virus transmission occurs by the fecal-oral route, with person-to-
person and food- or waterborne spread being the most common
(5). The economic impact of these infections is staggering, with an
economic cost for norovirus (NoV)-associated food-borne out-
breaks alone of $5.8 billion annually in the United States (6). Un-
fortunately, no specific therapies are currently available to control
or prevent HuNoV infections.
HuNoV research has been stifled by the absence of a HuNoV
cell culture system and a genetically manipulable small-animal
model for HuNoV. Some aspects of HuNoV biology have been
studied in chimpanzees (7), gnotobiotic pigs, and calves (8, 9).
However, these large-animal models are cumbersome, expensive,
and not widely available.
HuNoVs are single-stranded positive-sense [()-sense] RNA
viruses in the Caliciviridae family (10). Their ~7.5-kb genome
encodes three open reading frames (ORFs). ORF1 encodes the
nonstructural proteins N-terminal protein or NS1/2, NTPase or
NS3, 3A-like protein or NS4, VPg (viral protein, genome-linked)
or NS5, protease or NS6, and RNA-dependent RNA polymerase
(RdRp) or NS7, while ORF2 and -3 encode the major and minor
capsid proteins VP1 and VP2, respectively (10). HuNoVs are clas-
sified based on sequence similarity into three genogroups (GI, GII,
and GIV) and at least 25 genotypes (11). However, the majority of
HuNoV strains causing outbreaks today belong to the GII, geno-
type 4 (GII.4) cluster (12). Over the past decade, GII.4 epidemics
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have occurred every 2 to 3 years, with new strains emerging by
mutation and recombination (13), including the most recent
GII.4 variant, Sydney 2012 (14).
To combat the problem of HuNoV morbidity and mortality, a
widely accessible, genetically manipulable, small-animal platform
and reproducible tissue culture system are urgently needed to in-
vestigate molecular mechanisms regulating HuNoV infection and
to develop effective antiviral strategies (15). Here we report over-
coming one of these major barriers in the field through the devel-
opment of the first mouse model for HuNoV.
RESULTS
Reconstitution of a humanized immune system is not required
for susceptibility of mice to HuNoV. HuNoV antigen is detected
in B lymphocytes and dendritic cells in the intestinal lamina pro-
pria of HuNoV-infected chimpanzees (7), and a HuNoV GII.4
strain binds to cells in the lamina propria of human duodenum in
an in vitro whole-virus binding assay (16). This raised the possi-
bility that HuNoV may replicate in human immune cells. To test
whether human immune cells are important for HuNoV infec-
tion, we used “humanized” mice (i.e., mice engrafted with human
CD34 hematopoietic stem cells to reconstitute a functional hu-
man immune system) (35). Recombination activation gene (Rag)
1 or 2- and common -chain (c)-deficient (Rag/ c/)
BALB/c mice were irradiated 2 to 3 days after birth and injected
with human CD34 hematopoietic stem cells, as previously de-
scribed (17). Approximately 6 months later, when these mice had
reconstituted a human immune system, seven humanized mice,
five nonhumanized Rag/ c/ mice, and six BALB/c wild-type
mice were challenged with pooled stool suspensions from patients
containing either GI and GII (GIII mix) or only GII (GII mix)
HuNoV strains (see Table S1 in the supplemental material and
Materials and Methods). Mice were infected with 8.56  103 GI
and 4.08  103  7.08  10e4 GII total genomes (for GIII mix)
or 7.45  103 GII total genomes (for GII mix) (see Table S2 in the
supplemental material).
Mice were initially challenged with pooled human stool sam-
ples by both the intraperitoneal and oral routes to increase the
chance of detecting HuNoV replication (Fig. 1; see also Table S2 in
the supplemental material). All tissue and fecal samples from the
12 humanized and nonhumanized mice were analyzed using mul-
tiplex quantitative reverse transcriptase PCR (qRT-PCR) as de-
scribed elsewhere (18) to measure GI and GII genome loads. No
GI sequences were detected in murine feces or tissues in any of the
7 mice infected with the GIII mix for 24 or 72 h postinfection
(hpi) (see Table S2 in the supplemental material). Therefore, only
pooled human stool suspensions containing GII viruses (GII mix)
were used for subsequent infections, in which mice were infected
for 48 or 72 hpi. None of the mice succumbed to infection, but one
humanized mouse with high titers in feces and tissue developed
FIG 1 HuNoV infects humanized and nonhumanized Rag/ c/ mice. Mice were infected intraperitoneally and orally with HuNoV-containing stool
filtrates. Symbols indicate the mouse background: open, Rag-c; filled, Rag-c-hu. Open triangles indicate wild-type (wt) mice. Inocula are colored blue (GIII
mix) or red (GII mix). (A) HuNoV genomes were measured by qRT-PCR in stomach (ST), jejunum/duodenum (JD), proximal ileum (PI), distal ileum (DI),
cecum (CE), and colon (CO), mesenteric lymph nodes (MLN), liver (LI), spleen (SP), kidney (KI), heart (HT), lung (LU), bone marrow (BM), and brain (BR)
from mice sacrificed 24 (top panel), 48 (middle panel), or 72 (bottom panel) hours postinfection (hpi). (B) HuNoV genomes were measured in total feces
excreted 12 h before infection (pre) or between 0 to 24, 24 to 48, or 48 to 72 hpi. (C) Total genome titers recovered from humanized (Rag-c-hu), nonhumanized
(Rag-c), and wild-type (WT) BALB/c mice at the time of harvest were compared to inoculum titers to determine the log fold increase in viral titer over inoculum.
Data are from at least two independent experiments, and each symbol represents titers from an individual mouse.
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watery diarrhea 24 hpi (mouse 3 in Table S2 in the supplemental
material; also data not shown).
Analysis of the tissue samples indicated that HuNoV GII ge-
nomes were detectable in tissues from both humanized (5/7) and
nonhumanized (4/5) mice (see Table S2 in the supplemental ma-
terial). Tissue titers peaked at 24 to 48 hpi but declined by 72 hpi
(Fig. 1A). HuNoV genomes were present in all regions of the in-
testine and in many of the extraintestinal sites (Fig. 1A; see also
Table S2 in the supplemental material). The tissue sites consis-
tently negative for HuNoV genome were brain and spleen. These
data suggest that HuNoV does not cross the blood-brain barrier of
humanized and nonhumanized mice.
Analysis of fecal samples indicated that GII genomes were de-
tected in feces from 9 out of 12 mice, with similar proportions of
humanized (5/7) and nonhumanized (4/5) mice (see Table S2 in
the supplemental material). No HuNoV genomes were detected in
murine feces prior to infection, but fecal titers peaked at 24 hpi
(Fig. 1B). Of the 8 mice with detectable HuNoV genome titers in
the tissues, only one had no detectable genome in the feces (see
Table S2 in the supplemental material, mouse 8). In analogy to
epidemiological analysis of HuNoV outbreaks (e.g., see reference
19), we obtained sequence information for HuNoV strains pres-
ent in murine feces. Genotyping of murine feces revealed the pres-
ence of GII.4 genotype in feces from 8 out of 9 mice with detect-
able fecal titers. A natural recombinant, GII.g/II.1, was the only
other genotype isolated from mouse feces. This GII strain exhibits
closest sequence homology in the polymerase region to GII.g
strains, while a region in the capsid aligned more closely with
those of GII.1 strains. Interestingly, no GII.g/II.1 genomes were
detected in the inoculum (see Table S1 in the supplemental mate-
rial), suggesting that this genotype may have been present in hu-
man stool in quantities below the limit of detection. A GII.6 ge-
notype that was detected in one of the human stools present in the
GII mix (see Table S1 in the supplemental material) was not re-
covered from infected mice (see Table S2 in the supplemental
material). Thus, the GII.4 isolate was detected predominantly in
murine feces, possibly because it was present at higher titers than
the other genotypes in the inoculum. Whether GI.3, GII.6, or
other genotypes are infectious at higher doses or in general needs
to be analyzed in the future to clarify the strain dependence in this
model.
Since qRT-PCR for HuNoV does not distinguish between in-
put and replication of HuNoV, genomes in tissues and murine
feces at the experimental endpoint were combined and compared
to the inoculum titer to determine whether HuNoV replicated in
mice. Four of seven humanized and four of five nonhumanized
animals showed 3- to 1,400-fold increases in genome titers over
input (Fig. 1C; see also Table S2 in the supplemental material).
This analysis suggested that HuNoV replicated in 9 of 12 mice
following a combined intraperitoneal and oral challenge. No sta-
tistically significant difference using the Mann-Whitney U test (P
 1.000) was observed in the log fold increase between the hu-
manized and nonhumanized mice challenged with HuNoV. Six
BALB/c mice infected with the GII mix (1.47  105 GII genome
copies total/mouse) intraperitoneally and orally showed no in-
creases in genome loads over input (Fig. 1C). Taken together,
these data suggest that HuNoV infection of Rag/ c/ mice
can occur in the absence of human immune cells and show that
the immunodeficiency conferred by the lack of Rag and/or c is
required for HuNoV replication in mice.
Minimal changes occurred in the fecal GII.4 HuNoV se-
quence. Adaptation of human viruses is frequently required to
establish robust infection in a mouse model (e.g., see reference
20). To determine whether HuNoV adapted to its murine host, we
determined the complete sequence from an inoculating human
stool sample (sample 9 [see Table S1 in the supplemental mate-
rial]) (norovirus Hu/GII.4/MI002/2011/USA) by 454 sequencing
and compared it to the genome sequence collected from diarrhetic
mouse feces 48 hpi (mouse 3 [see Table S2]) (norovirus Hu/GII.4/
MI001/2011/USA) obtained by direct sequencing of PCR contigs.
Only two silent nucleotide exchanges in the genome (C1576G in
NS3 [NTPase] and T3058C in NS6 [protease]) were identified
(data not shown), suggesting that HuNoV present in the murine
feces did not undergo extensive adaptation. However, the meth-
odologies used preclude us from determining whether the full-
length genomic sequence determined from the feces of the diar-
rhetic mouse represents input or replicated virus.
Rag/ c/ mice are susceptible to infection by the intra-
peritoneal route. The previous studies suggested that nonhuman-
ized BALB/c Rag/ c/ mice could be infected with GII.4
HuNoV following a combined intraperitoneal and oral challenge.
Therefore, each route was tested individually. Eight BALB/c
Rag/ c/ mice were infected orally with 0.05 ml GII mix
containing 2.80  105 GII genome copies for 24 or 48 hpi, while 13
mice were infected intraperitoneally with 0.2 ml GII mix contain-
ing 1.11  10e5  4.63  106 GII genome copies. Tissues and feces
were collected and analyzed as described above (Fig. 2; see also Fig.
S1 in the supplemental material).
In the orally inoculated mice, no genomes were detectable in
any of the regions of the intestine and extraintestinal sites (see
Fig. S1A in the supplemental material). Five of eight mice had
detectable GII genomes in their feces during the first 24 h of in-
fection, while no genomes were detectable prior to and between 24
and 48 hpi (see Fig. S1B in the supplemental material), suggesting
FIG 2 HuNoV infects Rag/ c/ mice by the intraperitoneal route.
BALB/c Rag/ c/ mice were infected intraperitoneally with 1.11  10e5
 4.63  106 genomes of HuNoV GII mix for 24 (A) or 48 (B) hours. HuNoV
genomes in tissues (abbreviations as in Fig. 1) were measured by qRT-PCR.
Data are from four independent experiments, and each symbol represents
titers from an individual sample.
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that the detected genome was from input virus. No increases in
viral loads over input were measured (data not shown). These data
indicate that nonhumanized BALB/c Rag/ c/ mice were not
infected orally.
All 13 mice infected intraperitoneally had detectable genome
titers in tissues at 24 or 48 hpi (Fig. 2). Viral genomes were de-
tected in the intestine and extraintestinal sites, except in the brain.
However, no virus was detected in the feces, suggesting that
BALB/c Rag/ c/ mice do not shed virus following intraperi-
toneal infection (Fig. 2). Overall, 12 of the 13 mice had 3- to
60-fold increases in combined genome titers in the tissues com-
pared to the inoculum titer (Fig. 3). As a control, two mice were
infected intraperitoneally with 0.2 ml GII mix containing 1.32 
10e5 GII genome copies for 3 h, a time point prior to replication,
and analyzed as before. No increases in genome titer over input
were detected, suggesting that detection of increased genome ti-
ters over input titers depends on the ability of HuNoV to replicate.
These data suggest that the intraperitoneal route facilitates a sub-
clinical GII.4 infection of BALB/c Rag/ c/ mice.
Susceptibility of mice to HuNoV infection is dependent on
the genetic background of the host. Commercial availability of a
mouse strain susceptible to HuNoV would greatly facilitate use of
this mouse model. Therefore, Rag/ c/ mice on a mixed
C57BL/6J  C57BL/10SgSnAi background were purchased from
Taconic Farms (model no. 4111) and tested for susceptibility to
HuNoV. In three independent experiments, groups of five
C57BL/6J  C57BL/10SgSnAi Rag/ c/ mice were infected
intraperitoneally with 0.2 ml GII mix containing 6.35  105 to
1.22  106 genome copies. Tissues and murine feces were ana-
lyzed as before. Viral genomes were only detected in some tissues
(stomach, jejunum/duodenum, liver, spleen, mesenteric lymph
nodes, and kidney) of 4 out of 15 mice (data not shown). No
genomes were detectable in the feces of any of these mice (data not
shown). Only 4 of 15 Rag/ c/ mice on the C57BL/6J 
C57BL/10SgSnAi background showed increased tissue genome
loads over input (Fig. 3). There was a highly significant difference
in fold increase between Rag/ c/ mice on the BALB/c back-
ground and Rag/ c/ mice on the C57BL/6J  C57BL/
10SgSnAi background as determined using the Mann-Whitney
U test (P  0.0001) (Fig. 3). These data demonstrate that Rag/
c/ mice on a BALB/c background are more susceptible to
HuNoV infection and suggest that genetic factors of the host are
important mediators of susceptibility.
Cells with macrophage-like morphology stain positive for
HuNoV nonstructural and structural proteins. To confirm
HuNoV replication and investigate the cell tropism of HuNoV,
immunohistochemistry was performed on sections of the small
intestine, spleen, and liver from BALB/c Rag/ c/ mice in-
fected intraperitoneally with GII mix for 24 and 48 h, shown in
Fig. 3. To detect the viral capsid protein VP1, a polyclonal rabbit
serum raised against virus-like particles (VLPs) from GII.7
HuNoV was used, since intragenogroup cross-reactive antibodies
develop following VLP immunization (21). Rabbit antibodies
were also raised against conserved antigenic peptide sequences in
NS4 and NS6 from GII.4 strains (including KC631814 and
KC631815 described herein). Preimmune sera and staining of tis-
sue sections from mock-infected animals were used as controls.
Translation of nonstructural proteins from genomic RNA is a
hallmark of ()-sense RNA virus replication and has been used by
others to demonstrate HuNoV replication in an animal model (8).
In the case of BALB/c Rag/ c/ mice, HuNoV NS4- and
NS6-positive cells with macrophage-like morphology were ob-
served in the splenic white pulp at the margins of the periarteriolar
lymphocyte sheath spleen and in Kupffer cells of infected but not
mock-infected mice (Fig. 4A, C, E, G, I, K, M, and O). No NS4- or
NS6-positive cells were detected in the intestine (data not shown).
Tissue sections from HuNoV-infected or mock-infected mice
probed with the respective preimmune control sera were negative,
demonstrating specificity of the antisera (Fig. 4B, D, F, H, J, L, N,
and P).
In addition to expression of nonstructural proteins from full-
length genomes, capsid proteins are expressed from subgenomic
RNAs during norovirus replication (10). Therefore, sections of
intestine, spleen, and liver were also stained with HuNoV VP1
antiserum. Similar to the case with NS4 and NS6 expression,
capsid-specific staining was observed in cells with macrophage-
like morphology in the intestine, in the white pulp of spleen, and
in Kupffer cells (Fig. 5). To determine whether detection of capsid
protein in these antigen-presenting cells resulted from input or
replicated virus, we infected two BALB/c Rag/ c/ mice in-
traperitoneally with GII mix (1.32  10e5 genome copies) for 3 h,
a time point prior to replication. Tissue sections from liver and
spleen were analyzed by immunohistochemistry as before, but no
staining was observed (data not shown). These data indicate that
capsid protein from incoming virions cannot be detected by this
staining protocol, providing indirect evidence for virus replica-
tion, which results in generation of subgenomic RNA and trans-
lation of capsid proteins.
Murine NoV (MNV) is a highly prevalent pathogen in biomed-
ical research colonies (22). Although RAG/ c/ mice in our
colony repeatedly tested negative by qRT-PCR for MNV (data not
shown), we nevertheless directly examined the potential of the
HuNoV antibodies to cross-react with MNV (see Fig. S2 in the
supplemental material). Two RAG/ c/ mice were infected
with 1.5  105 PFU of MNV-1.CW3 by the intraperitoneal (i.p.)
route for 24 h. MNV-1 titers in the spleen were 1.1  104 PFU/ml
(or 5.04  107 genome copies/spleen), and titers in the liver were
3.6  103 PFU/ml (or 3.28  107 genome copies/liver). Immuno-
histochemistry analysis of liver and spleen sections with anti-
HuNoV VP1, -NS4, and -NS6 antibodies revealed no cross-
reactivity with MNV antigens (see Fig. S2A to C and E to G in the
supplemental material). As a positive control, liver and spleen
sections were stained with an anti-MNV VP1 antiserum, and
FIG 3 Susceptibility of Rag/ c/ mice to HuNoV is determined in part
by the genetic background of the host. Rag/ c/ mice on a BALB/c or
mixed C57BL/6J  C57BL/10SgSnAi background were infected intraperito-
neally with HuNoV GII mix. HuNoV genomes measured in mice at 24 (filled
symbols) or 48 hpi (open symbols) were compared to the inoculum to deter-
mine the log fold increase in viral genomes over input. Data are from at least
three independent experiments. The mean  SEM is indicated for each data
set. Data were analyzed using the Mann-Whitney U test. ****, P  0.0001.
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MNV antigens were detected in Kupffer cells in the liver and
macrophage-like cells in the spleen (Fig. S2D and H in the supple-
mental material), similar to our previous findings (23). Taken
together, these data demonstrate that the HuNoV antisera did not
cross-react with MNV antigens.
Overall, the numbers and patterns of HuNoV NS4-, NS6-, and
VP1-positive cells in liver and spleen tissue were the same as those
observed with anti-MNV VP1-stained liver and spleen sections
and revealed a low number of individual antigen-positive cells
scattered throughout the tissue (Fig. 4; see also Fig. S2 in the sup-
plemental material; data not shown). While the low number of
antigen-positive cells is likely driven by the low sensitivity of the
immunohistochemistry assay, the pattern of scattered, individual
antigen-positive cells of hematopoietic origin is also seen in other
enteric calicivirus infections (7, 24, 25).
Histopathological analysis of hematoxylin-and-eosin-stained
sections from liver, spleen, kidney, and small intestine of HuNoV-
infected mice did not reveal significant changes compared to find-
ings for mock-infected animals (data not shown), similar to find-
ings in gnotobiotic pigs infected with HuNoV (8).
Taken together, these data provide evidence for expression of
nonstructural proteins from genomic RNAs and capsid protein
from subgenomic RNAs, strongly suggesting that HuNoV repli-
cates in cells of the macrophage lineage in BALB/c Rag/ c/
mice.
DISCUSSION
Study of HuNoV biology and development of antiviral therapies is
hampered by the lack of a small-animal model. To overcome this
limitation, the goal of these studies was to develop a HuNoV
FIG 4 HuNoV nonstructural antigen staining in macrophage-like cells. Immunohistochemistry was performed with sections of spleen (E to H and M to P) or
liver (A to D and I to L) using anti-NS4-specific (A, C, E, and G) or anti-NS6-specific (I, K, M, and O) immune or the respective preimmune sera (NS4 preimmune
[B, D, F, and H] or NS6 preimmune [J, L, N, and P]) from Rag/ c/ mice infected intraperitoneally with GII mix (A, B, E, F, I, J, M, and N) or mock stool
(C, D, G, H, K, L, O, and P) for 24 h. Magnified antigen-positive cells are shown in picture insets. Scale bar  50 m.
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mouse model. Our data demonstrate that humanized and nonhu-
manized Rag/ c/ mice on a BALB/c background were sus-
ceptible to a subclinical infection with HuNoV as indicated by
detection of nonstructural protein-positive cells and capsid-
positive cells, as well as increases in genome titers over input.
First, expression of nonstructural proteins, which are ex-
pressed only during infection (10), has been used in the case of
HuNoV infection of gnotobiotic pigs (8) as one line of evidence to
demonstrate HuNoV replication. Similarly, our data show that
two independent antibodies directed against two nonstructural
proteins detected antigen-positive cells in infected but not mock-
infected mice (Fig. 4). Furthermore, the corresponding preim-
mune sera did not react with any antigens, and no cross-reactivity
with the related MNV nonstructural proteins was observed.
Second, subgenomic RNAs are made during replication to ex-
press the noroviral capsid protein (10). Thus, detection of capsid
protein at levels greater than those of incoming capsids is addi-
tional evidence for HuNoV replication and was used in several
other HuNoV animal models (7, 8, 9). We detected capsid protein
expression in livers and spleens of mice infected intraperitoneally
with HuNoV for 24 h but failed to detect capsid-positive cells in
the livers and spleens of mice infected for 3 h (Fig. 5 and data not
shown). This demonstrated that capsid protein from input virus
cannot be detected by immunohistochemistry and suggested that
the capsid protein detected at 24 hpi was translated from newly
synthesized viral subgenomic RNA. The number and pattern of
HuNoV nonstructural protein-positive cells in liver and spleen
tissue was similar to that observed using an antibody against the
HuNoV capsid protein (Fig. 4 and 5), suggesting that translation
of nonstructural proteins, subgenomic replication, and transla-
tion of the capsid protein occurred in a single cell.
Third, increases in overall genome titers over input were used
as another independent piece of evidence of replication. Up to
1,400-fold increases over input were detected in genome titers in
mice infected by a combined oral/intraperitoneal administration,
and up to 60-fold increases were detected in mice infected intra-
peritoneally. The significant increases in genome titers over input
were observed in two independent laboratories. Moreover, the
likelihood that merely input virus in tissue samples was detected is
low because no increases over input virus were observed in mul-
tiple experiments in which mice were inoculated with HuNoV,
e.g., combined oral/intraperitoneal infection of wild-type BALB/c
mice (Fig. 1C), oral infection of Rag/ c/ mice (see Fig. S2
in the supplemental material), and intraperitoneal infection of
Rag/ c/ mice for 3 h, a time point prior to replication (data
not shown).
Our data further demonstrated that Rag/ c/ mice recon-
stituted with CD34-positive human stem cells showed no statisti-
cally significant difference from nonhumanized mice. Thus, sus-
ceptibility was not linked to human cell reconstitution in this
mouse model, and this suggested that HuNoV may replicate in
cells of murine origin. Immunohistochemistry of infected tissues
showed HuNoV capsid-, NS4-, and NS6-positive Kupffer cells
and macrophage-like cells in the spleen (Fig. 4 and 5). This is
similar to murine norovirus (MNV), where antigen-positive
Kupffer cells in the liver and splenic cells with macrophage-like
morphology were observed (23, 26) (see Fig. S2 in the supplemen-
tal material). A tropism of HuNoV for macrophages, a cell type
present in the intestinal lamina propria, is also consistent with the
previous finding that HuNoV GII.4 virus-like particles bind to
lamina propria cells of human duodenum tissue sections (16).
Thus, HuNoV and MNV may share a tropism for cells of the
hematopoietic lineage. The identification of a cell type from the
murine host, which supports HuNoV infection, may lead to the
development of a HuNoV tissue culture system in the future.
We also demonstrated that Rag/ c/ mice on a C57BL/6J
FIG 5 HuNoV capsid protein staining in macrophage-like cells. Immunohistochemistry was performed on sections of small intestine (A and D), spleen (B and
E), and liver (C and F) using anti-HuNoV VP1-specific immune (A to C) and preimmune (D to F) sera from Rag/ c/ mice infected intraperitoneally with
GII mix for 24 (A, B, D, and E) or 48 (C and F) h. Magnified antigen-positive cells are shown in picture insets. Scale bar  50 m.
Taube et al.
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 C57BL/10SgSnAi background were less susceptible to HuNoV
than Rag/ c/ mice on a BALB/c background. Therefore,
susceptibility may depend on the genetic background and/or im-
mune deficiencies. Differences in susceptibility due to genetic
backgrounds are also observed with other pathogens, and an in-
creased susceptibility of BALB/c mice compared to that of C57BL6
or C57BL10 mice due to differences in the host immune response
has been described (e.g., see references 27 to 29). For example,
production of type I interferons by peritoneal macrophages/
monocytes was significantly increased in C57BL6 mice over that in
BALB/c mice (27). HuNoV replication is sensitive to type I inter-
ferons (30, 31). Thus, HuNoV injected intraperitoneally in
C57BL/6J  C57BL/10SgSnAi mice potentially encounters higher
levels of type I interferons, which in turn could limit virus infec-
tion. Further studies will be required to identify host factors de-
termining HuNoV susceptibility in this mouse model.
Interestingly, our study suggests that Rag/ c/ mice are
not susceptible to oral infection. This is in contrast to HuNoV
transmission in humans, which occurs via the fecal-oral route,
and in gnotobiotic pigs, which are permissive to HuNoV follow-
ing oral infection (31). This lack of oral infection in Rag/ c/
mice may be due to the genetic deficiency in the common cytokine
receptor gamma chain (c) in these mice. Several enteric patho-
gens use specialized microfold (M) cells present in the follicle-
associated epithelium overlaying Peyer’s patches to gain access to
their host (for review, see reference 32). However, Peyer’s patches
were absent from Rag/ c/ mice following macroscopic and
histological observation (data not shown). This is not surprising,
since signaling through the interleukin 7 (IL-7) receptor, which is
a heterodimer comprised of the IL-7 alpha chain and common
gamma chain, is critical for Peyer’s patch development (33, 34).
We hypothesize that a lack of M cells may prevent oral HuNoV
infection in this mouse model, and studies are currently under
way to test this hypothesis.
In addition, we did not observe HuNoV genome in the feces of
mice following intraperitoneal infection alone at any of the ana-
lyzed time points. In contrast, viral genomes were detected in the
feces of mice infected both intraperitoneally and orally or orally
only. HuNoV genome titers in murine feces were less than input
levels following oral infection, suggesting that the viral genomes
detected represent input virus. Genome titers in murine feces
greater than that of input virus were detected when mice were
infected by combined intraperitoneal and oral inoculation. Future
studies are needed to determine the relative amounts of replicated
virus shed under these conditions. In addition, our finding raises a
broader unanswered question in norovirus pathogenesis, which is
how noroviruses are shed from their host. Rag/ c/ mice
may provide an important tool to address this question in the
future.
In summary, Rag/ c/ mice on a BALB/c background are
susceptible to a subclinical infection by HuNoV, providing the
first small-animal model for HuNoV infection. While this mouse
model does not recapitulate all aspects of HuNoV infection, such
as fecal-oral transmission, it will allow further mechanistic studies
of HuNoV biology, including host and viral factors determining
susceptibility, which might enable improvement of the mouse
model. Furthermore, it is our hope that the availability of an easily
manipulable small-animal model for HuNoV infection will facil-
itate not only basic but also translational HuNoV research, such as
efficacy testing of compounds with anti-HuNoV activity, thereby
accelerating the development of urgently needed HuNoV thera-
peutics.
MATERIALS AND METHODS
Detailed methods can be found in Text S1 in the supplemental material.
HuNoV samples. Ten human stool samples from confirmed HuNoV
outbreaks (see Table S1 in the supplemental material) were processed as
outlined in Text S1.
Mice. All animal studies described herein were performed in accor-
dance with local and federal guidelines. Please refer to Text S1 in the
supplemental material for details.
Infection of mice. Mice were housed individually in wire-bottom
cages, and murine feces were collected over the indicated time frames.
Mice were infected and harvested as outlined in Text S1.
Quantification/typing of HuNoV genomes by qRT-PCR. Quantita-
tive RT-PCR of the HuNoV genome was performed with total RNA from
fecal and tissue samples as detailed in Text S1 in the supplemental mate-
rial. The sensitivity and specificity of the assay are outlined in Text S1.
Fecal samples were subjected to genotyping as detailed in Text S1.
Determination of fold increase. Inoculum titers were determined for
each experiment after back titration of the human stool suspensions by
qRT-PCR. Total genome copies per mouse were calculated by adding
genome copies in all tissues and feces as outlined in Text S1 in the supple-
mental material. The fold change was determined by dividing total ge-
nome copies by inoculum genome copies.
Sequencing. Total nucleic acid was isolated from 0.2 ml of clarified
human stool filtrate of patients 9 and 10 (see Table S1 in the supplemental
material), and 454 pyrosequencing was performed. A genome sequence of
HuNoV GII was obtained from mouse feces 48 h postinfection using
Sanger sequencing of PCR amplicons (GenBank no. KC631815) (see Text
S1 for additional details).
Generation of antibodies. Anti-VLP antibodies were made at Co-
calico Biologicals, Inc., Reamstown, PA, in rabbits, following standard
protocols. Nonstructural antibodies against conserved antigenic NS4 and
NS6 peptide sequences were generated and were affinity purified at Gen-
Script USA Inc., Piscataway, NJ, in rabbits, following standard protocols.
Preimmune sera were collected from each rabbit used to generate each
antibody (see Text S1 in the supplemental material for additional details).
Histopathology and immunohistochemistry. Mouse tissues were
fixed and processed at the University of Michigan Pathology Core for
Animal Research, following standard histological procedures (see Text S1
in the supplemental material for additional details).
Statistical analysis. The software program GraphPad Prism V5
(GraphPad, La Jolla, CA) was used to perform statistical analyses. The
Mann-Whitney U test was used to analyze differences. Results were con-
sidered statistically significant when the P value was 0.05.
Nucleotide sequence accession numbers. The genomic sequences for
the HuNoV GII strain obtained from feces of the mouse with diarrhea
(norovirus Hu/GII.4/MI001/2011/USA; accession number KC631814),
the original inoculum (norovirus Hu/GII.4/MI002/2011/USA; accession
number KC631815), and the GII.7 HuNoV used for VLP production (ac-
cession number KC832474) have been deposited in GenBank.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.00450-13/-/DCSupplemental.
Text S1, DOCX file, 0.1 MB.
Figure S1, TIF file, 1.1 MB.
Figure S2, TIF file, 6.5 MB.
Table S1, XLSX file, 0.1 MB.
Table S2, XLSX file, 0.1 MB.
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